Does risk of embryonic malformations outweigh benefits of using SSRIs in pregnant women?

Does risk of embryonic malformations outweigh benefits of using SSRIs in pregnant women?
Credit: Mary Ann Liebert, Inc., publishers

A comprehensive new review article presents the most current understanding of the role selective serotonin reuptake inhibitors (SSRIs) play in increased risk of multiple diverse gestational malformations and takes aim at the ongoing debate over whether SSRIs as a drug class can cause these malformations. The article, which also highlights the importance of serotonin—a key mediator of bioelectric control mechanisms—in normal embryonic development, is published in the preview issue of Bioelectricity.

Entitled "Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Major Malformations: The Importance of Serotonin for Embryonic Development and the Effect of Serotonin Inhibition on the Occurrence of Malformations," the article was coauthored by Anick Bérard, Ph.D., University of Montreal (Quebec, Canada), Michael Levin, Ph.D., Tufts University (Medford, MA), Thomas Sadler, Ph.D., University of Utah School of Medicine (Salt Lake City), and David Healy, MD, Hergest Unit (Bangor, U.K.).

The researchers examined the body of research related to serotonin, its inhibition using SSRIs, and the relationship to embryonic development and malformations. SSRIs can disrupt in multiple ways, including through its effects on and on the activity of ion channels in cells, affecting bioelectric mechanisms and serotonergic cell signaling.

"This review is a particularly important contribution to the debate about SSRI use during pregnancy," says Dany Spencer Adams, Editor-in-Chief of Bioelectricity, from Tufts University, Medford, MA. "In addition to combining the epidemiological data with relevant evidence from model systems, it incorporates the newly recognized bioelectric mechanisms of SSRI effects, as well as empirical evidence for the role of in embryos prior to the development of the nervous system. It also proposes that widespread belief in the drug's safety could result from the focus on the lower incidence of particular phenotypes, such as heart malformations, rather than recognizing the full variety of as resulting from a single common cause—disruption of .


Explore further

Study focuses on atomic structure of the serotonin transporter bound to SSRIs

More information: Anick Bérard et al, Selective Serotonin Reuptake Inhibitor Use During Pregnancy and Major Malformations: The Importance of Serotonin for Embryonic Development and the Effect of Serotonin Inhibition on the Occurrence of Malformations, Bioelectricity (2018). DOI: 10.1089/bioe.2018.0003
Provided by Mary Ann Liebert, Inc
Citation: Does risk of embryonic malformations outweigh benefits of using SSRIs in pregnant women? (2018, October 15) retrieved 23 February 2019 from https://medicalxpress.com/news/2018-10-embryonic-malformations-outweigh-benefits-ssris.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
4 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more